Proof of Market Assessment for an Intra- Operative Molecular Imaging Camera

在英国，每年有4.5万人被诊断患有乳腺癌，其中1.2万人将死于这种疾病。手术是乳腺癌的主要治疗选择，然而对于五分之一的患者来说，手术后肿瘤会复发。隐藏在肿瘤切除边缘的癌组织是导致肿瘤术后复发的主要因素。因此，为外科医生提供更好的工具来检测手术中的癌症组织是一个巨大的医学需求。Artemis诊断有限公司正在开发一种新型的术中分子成像摄像机，它将使外科医生能够在手术过程中实时“看到”癌组织，并相应地指导切除。该相机可以检测癌症的分子特征，从而扩大了外科医生的视野诊断范围。在手术中能够看到癌组织将使外科医生能够更准确地进行肿瘤切除。这将减少肿瘤复发的可能性，同时保留健康的组织。在这个市场研究项目中，我们将收集外科医生对摄像设备的反馈，以完善系统设计，估计采用率，并确定哪些手术病例将最大限度地受益于这项技术。

Each year, 45,000 people in the UK are diagnosed with breast cancer, and 12,000 people will die from the disease. Surgery is the primary treatment option for breast cancer, yet for 1 in 5 patients the tumor will recur following surgery. Cancerous tissue hidden in the borders of the tumor resection is the the main contributor to tumor recurrence following surgery. Consequently, there is a tremendous medical need to give surgeons better tools to detect cancerous tissue during surgery.Artemis Diagnostics LTD is developing a novel intra-operative molecular imaging videocamera that will enable surgeons to "see" cancerous tissue in real-time during the operation and guide the resection accordingly. The camera can detect molecular signatures of cancer, thereby extending the diagnostic range of the surgeon's vision. Being able to see cancerous tissue during the operation will enable the surgeon to perform more accurate tumor resections. This will lessen the likelihood of tumor recurrence while preserving healthy tissue. In this market research project, we will collect surgeons' feedback on the camera device to refine the system design, estimate the adoption rate, and determine which surgical cases would most benefit from the technology.